SI2155229T1 - Sestavek za transmukozno dajanje polipeptidov - Google Patents
Sestavek za transmukozno dajanje polipeptidovInfo
- Publication number
- SI2155229T1 SI2155229T1 SI200830213T SI200830213T SI2155229T1 SI 2155229 T1 SI2155229 T1 SI 2155229T1 SI 200830213 T SI200830213 T SI 200830213T SI 200830213 T SI200830213 T SI 200830213T SI 2155229 T1 SI2155229 T1 SI 2155229T1
- Authority
- SI
- Slovenia
- Prior art keywords
- biologically active
- transmucosal
- active polypeptide
- polypeptides
- dosage form
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 238000010521 absorption reaction Methods 0.000 abstract 3
- 239000002552 dosage form Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 239000003833 bile salt Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 210000004400 mucous membrane Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92700607P | 2007-05-01 | 2007-05-01 | |
PCT/US2008/005655 WO2008137054A2 (en) | 2007-05-01 | 2008-05-01 | Composition for transmucosal delivery of polypeptides |
EP08754187A EP2155229B1 (en) | 2007-05-01 | 2008-05-01 | Composition for transmucosal delivery of polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2155229T1 true SI2155229T1 (sl) | 2011-05-31 |
Family
ID=39944167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200830213T SI2155229T1 (sl) | 2007-05-01 | 2008-05-01 | Sestavek za transmukozno dajanje polipeptidov |
Country Status (19)
Country | Link |
---|---|
US (2) | US20100111902A1 (sl) |
EP (2) | EP2316472A1 (sl) |
JP (1) | JP5611033B2 (sl) |
CN (1) | CN101674843A (sl) |
AT (1) | ATE495753T1 (sl) |
AU (1) | AU2008248228B2 (sl) |
CA (1) | CA2685853A1 (sl) |
CY (1) | CY1111422T1 (sl) |
DE (1) | DE602008004656D1 (sl) |
DK (1) | DK2155229T3 (sl) |
ES (1) | ES2359875T3 (sl) |
HK (1) | HK1141444A1 (sl) |
HR (1) | HRP20110273T1 (sl) |
IL (1) | IL201563A (sl) |
MX (1) | MX2009011784A (sl) |
NZ (1) | NZ580967A (sl) |
PL (1) | PL2155229T3 (sl) |
SI (1) | SI2155229T1 (sl) |
WO (1) | WO2008137054A2 (sl) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102770152B (zh) * | 2009-11-25 | 2016-07-06 | 阿瑞斯根股份有限公司 | 肽类的粘膜递送 |
RU2519099C1 (ru) * | 2012-11-08 | 2014-06-10 | Федеральное государственное бюджетное учреждение науки Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А.В. Топчиева Российской академии наук (ИНХС РАН) | Фармацевтическая композиция |
CN104667254A (zh) * | 2013-11-29 | 2015-06-03 | 中国科学院兰州化学物理研究所 | 一种鱼低聚肽泡腾片及其制备方法 |
CN104840958B (zh) * | 2015-05-28 | 2018-03-30 | 广州帝奇医药技术有限公司 | 人工粘膜组合物及其制备方法和应用 |
IT201700120081A1 (it) * | 2017-10-23 | 2019-04-23 | Biofarma S P A | Dispositivo e metodo per la somministrazione orale di principi attivi |
WO2019082221A2 (en) * | 2017-10-23 | 2019-05-02 | Biofarma S.P.A. | DEVICE AND METHOD FOR ORAL ADMINISTRATION OF ACTIVE PRINCIPLES |
CN112074286A (zh) | 2018-01-23 | 2020-12-11 | 吉拉毒蜥治疗公司 | 肽yy药物制剂、组合物和方法 |
EP3972582A4 (en) * | 2019-05-20 | 2023-10-04 | Poviva Corp. | COMPOSITIONS MTI BIOLOGICAL ACTIVE INGREDIENTS AND BILE SALTS |
WO2020243538A1 (en) * | 2019-05-31 | 2020-12-03 | Primo Pharmatech Llc | Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient |
US11291701B1 (en) * | 2021-02-04 | 2022-04-05 | Seed Edibles | Orally disintegrating, sublingual and buccal formulations |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US169989A (en) * | 1875-11-16 | Improvement in iron fences | ||
US2735304A (en) | 1956-02-21 | toppfb haw | ||
US142198A (en) * | 1873-08-26 | Improvement in windmills | ||
US142197A (en) * | 1873-08-26 | Improvement in fanning-mills | ||
US2613204A (en) | 1952-10-07 | of urea | ||
US163838A (en) * | 1875-06-01 | Improvement in mariners compasses | ||
GB697914A (en) | 1949-10-24 | 1953-09-30 | Ruf Buchhaltung Ag | Improvements in and relating to a sheet feeding and guiding device for a typewriter |
BE502283A (sl) | 1950-03-31 | |||
US4849227A (en) * | 1986-03-21 | 1989-07-18 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
JP2911496B2 (ja) | 1989-09-11 | 1999-06-23 | 帝國製薬株式会社 | 生理活性ポリペプチド含有高吸収性経膣剤 |
US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
EP0566135A1 (en) | 1992-04-17 | 1993-10-20 | Takeda Chemical Industries, Ltd. | Transmucosal composition comprising a peptide and a cytidine derivative |
US5503846A (en) | 1993-03-17 | 1996-04-02 | Cima Labs, Inc. | Base coated acid particles and effervescent formulation incorporating same |
US5766620A (en) * | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
DK1015352T3 (da) | 1997-04-01 | 2008-01-14 | Cima Labs Inc | Blisteremballage og emballerede tabletter |
US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
US6974590B2 (en) | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
US6200604B1 (en) * | 1998-03-27 | 2001-03-13 | Cima Labs Inc. | Sublingual buccal effervescent |
US20050158408A1 (en) * | 1998-07-24 | 2005-07-21 | Yoo Seo H. | Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
US6210699B1 (en) | 1999-04-01 | 2001-04-03 | Watson Pharmaceuticals, Inc. | Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity |
EP1708685B1 (en) | 2003-12-31 | 2011-03-09 | Cima Labs Inc. | Effervescent oral opiate dosage forms and methods of administering oxycodone |
PT1708686E (pt) | 2003-12-31 | 2011-04-20 | Cima Labs Inc | Forma de dosagem de fentanil oral efervescente geralmente linear e métodos de administração |
WO2005065317A2 (en) | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Effervescent oral fentanyl dosage form |
-
2008
- 2008-05-01 EP EP11151281A patent/EP2316472A1/en not_active Withdrawn
- 2008-05-01 DE DE602008004656T patent/DE602008004656D1/de active Active
- 2008-05-01 DK DK08754187.6T patent/DK2155229T3/da active
- 2008-05-01 CN CN200880014387A patent/CN101674843A/zh active Pending
- 2008-05-01 NZ NZ580967A patent/NZ580967A/en unknown
- 2008-05-01 PL PL08754187T patent/PL2155229T3/pl unknown
- 2008-05-01 WO PCT/US2008/005655 patent/WO2008137054A2/en active Application Filing
- 2008-05-01 CA CA002685853A patent/CA2685853A1/en not_active Abandoned
- 2008-05-01 JP JP2010506325A patent/JP5611033B2/ja not_active Expired - Fee Related
- 2008-05-01 AU AU2008248228A patent/AU2008248228B2/en not_active Ceased
- 2008-05-01 MX MX2009011784A patent/MX2009011784A/es active IP Right Grant
- 2008-05-01 SI SI200830213T patent/SI2155229T1/sl unknown
- 2008-05-01 ES ES08754187T patent/ES2359875T3/es active Active
- 2008-05-01 EP EP08754187A patent/EP2155229B1/en not_active Not-in-force
- 2008-05-01 AT AT08754187T patent/ATE495753T1/de active
-
2009
- 2009-10-15 IL IL201563A patent/IL201563A/en not_active IP Right Cessation
- 2009-10-30 US US12/609,998 patent/US20100111902A1/en not_active Abandoned
-
2010
- 2010-08-17 HK HK10107847.8A patent/HK1141444A1/xx not_active IP Right Cessation
-
2011
- 2011-04-14 HR HR20110273T patent/HRP20110273T1/hr unknown
- 2011-04-15 CY CY20111100380T patent/CY1111422T1/el unknown
- 2011-11-22 US US13/302,868 patent/US20120076757A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NZ580967A (en) | 2012-04-27 |
IL201563A (en) | 2013-05-30 |
CA2685853A1 (en) | 2008-11-13 |
DK2155229T3 (da) | 2011-05-09 |
JP5611033B2 (ja) | 2014-10-22 |
WO2008137054A2 (en) | 2008-11-13 |
AU2008248228A1 (en) | 2008-11-13 |
WO2008137054A3 (en) | 2009-06-04 |
EP2155229A2 (en) | 2010-02-24 |
AU2008248228B2 (en) | 2012-10-18 |
JP2010526071A (ja) | 2010-07-29 |
IL201563A0 (en) | 2010-05-31 |
US20100111902A1 (en) | 2010-05-06 |
DE602008004656D1 (de) | 2011-03-03 |
MX2009011784A (es) | 2009-11-13 |
HRP20110273T1 (hr) | 2011-05-31 |
ATE495753T1 (de) | 2011-02-15 |
HK1141444A1 (en) | 2010-11-12 |
EP2316472A1 (en) | 2011-05-04 |
EP2155229B1 (en) | 2011-01-19 |
US20120076757A1 (en) | 2012-03-29 |
PL2155229T3 (pl) | 2011-06-30 |
CY1111422T1 (el) | 2015-08-05 |
ES2359875T3 (es) | 2011-05-27 |
CN101674843A (zh) | 2010-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1141444A1 (en) | Composition for transmucosal delivery of polypeptides | |
WO2008027854A3 (en) | Pharmaceutical compositions comprising hgh for oral delivery | |
BRPI0418228A (pt) | forma de dosagem, e, métodos de tratamento de dor e de episódios de dor incidente de cáncer, e de preparação de um tablete para administração bucal, gengival ou sublingual de fentanil | |
CA2549642A1 (en) | Effervescent oral opiate dosage forms and methods of administering opiates | |
WO2005081742A3 (en) | Testosterone oral dosage formulations and associated methods | |
TW200612987A (en) | Combination treatment for non-hematologic malignancies | |
TW200744673A (en) | Improved ibandronate formulations | |
EA200501810A1 (ru) | Композиция конъюгированного лекарственного средства | |
WO2005065317A3 (en) | Effervescent oral fentanyl dosage form | |
CO5640120A2 (es) | Formulacion y metodods para el tratamiento de trombocitemia | |
BRPI0512756A (pt) | composição farmacêutica de combinação para o tratamento de dor, método de controle de dor, uso de uma composição e embalagem farmacêutica incluindo comprimidos ou cápsulas | |
WO2007061829A3 (en) | Pharmaceutical composition | |
IL196425A0 (en) | Pharmaceutical compositions containing ibuprofen and famotidine | |
DE602008006700D1 (sl) | ||
DK1641820T3 (da) | Fra RasGap afledt peptid til selektiv at dræbe kræftceller | |
IL179177A (en) | A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product | |
MXPA05010575A (es) | Peptacuerpo para el tratamiento del cancer. | |
TW200611697A (en) | Generally linear effervescent oral fentanyl dosage form and methods of administering | |
NO20024673L (no) | Farmasöytisk sammensetning med kontrollert frigivning for oral anvendelse inneholdende midodrin og/eller desglymidodrin | |
HK1126790A1 (en) | Biologically active peptide vapeehptllteaplnpk derivatives | |
WO2008133952A3 (en) | Transmucosal treatment with fentanyl in patients with mucositis | |
RU2004135668A (ru) | Способ иммунокоррекции у коров | |
TW200611696A (en) | Effervescent oral fentanyl dosage form and methods of administering fentanyl | |
AR048000A1 (es) | Forma de dosificacion oral efervescente substancialmente lineal de fentanilo y metodos de administracion | |
AR047999A1 (es) | Forma de dosificacion oral efervescente de fentanilo y metodos de administracion de fentanilo |